1. Academic Validation
  2. In vitro and in vivo pharmacokinetics and metabolism of MK-8353 by liquid chromatography combined with diode array detector and Q-Exactive-Orbitrap tandem mass spectrometry

In vitro and in vivo pharmacokinetics and metabolism of MK-8353 by liquid chromatography combined with diode array detector and Q-Exactive-Orbitrap tandem mass spectrometry

  • J Pharm Biomed Anal. 2019 May 10;168:64-74. doi: 10.1016/j.jpba.2019.02.012.
Jingru Gong 1 Zhe Jiang 1 Tao Yang 1 Yahong Zhu 2
Affiliations

Affiliations

  • 1 Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800 Gongwei Road, Pudong, Shanghai, 201399, China.
  • 2 Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800 Gongwei Road, Pudong, Shanghai, 201399, China. Electronic address: [email protected].
Abstract

In this study, a simple and sensitive quantitation method based on liquid chromatography combined with diode array detector and Q-Exactive-Orbitrap tandem mass spectrometry was developed for the determination of MK-8353 in rat plasma. The chromatographic separation was carried out on a Waters ACQUITY BEH C18 column by using water containing 1 mM ammonium acetate and acetonitrile containing 0.1% formic acid as mobile phase. The developed assay was linear (r > 0.999) over the concentration range of 1-1000 ng/mL. The selectivity, precision, accuracy, recovery, matrix effects and stability were all within the required limits. The validated assay has been further applied to the pharmacokinetic study of MK-8353 in rat after intravenous and oral administration, which revealed that MK-8353 showed low clearance and satisfactory bioavailability. More importantly, the metabolites of MK-8353 present in rat plasma, RLM, DLM and HLM were identified and profiled. Under the current conditions, a total of 10 metabolites were detected and their chemical structures were proposed in terms of the accurate masses and their fragment ions. Our results revealed that MK-8353 was metabolized mainly through dealkylation, demethylation, depropylation, oxygenation, sulfur oxidation and formation of lactam. Compared with animal species, no human-specific metabolite was found in HLM. This study provides overall in vitro and in vivo profiles of MK-8353, which is of great help in understanding its PK/PD profiles and in predicting human pharmacokinetic profiles.

Keywords

Bioavailability; MK-8353; Metabolic pathways; Pharmacokinetics.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50846
    99.27%, ERK1/2 Inhibitor
    ERK